Mission: Ongoing! China Looks To Align With FDA In Landmark IND Push
Executive Summary
Issuing new guidance for INDs, doubling reviewers, adopting priority and accelerated reviews, and cutting a submission backlog are among the raft of measures the China FDA is quietly but assertively taking to accelerate new drug approvals and support innovation.
You may also be interested in...
China Regulatory Shakeup: Top Regulator Out, Commissioner Reprimanded Amid Vaccine Scandal
Amid aftermath of latest vaccine scandal, top officials including China’s drug reform flagbearer are forced to resign, sending shock waves across the industry.
Bring On Clinical Studies: China Steps Up To Facilitate New Drug Entry
Allowing early stage Phase I studies, setting a 60-day period for IND approvals, and dropping a requirement for hospital to get certified, the China FDA proposes fundamental changes that would allow any qualified sites to file for approval to get studies rolling.
China Keeping Eye On Key Regulatory Dialog After Trump Win
Although Chinese President Xi Jinping has expressed the country's willingness to work with the newly elected US president to promote ties in a constructive way, potential setbacks for bilateral trade and regulatory talks are worrying observers.